brexpiprazole
Also known as OPC 34712, OPC-34712
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.
Key facts
- Drug.MedlinePlus
- a615046
- Drug.image
- Brexpiprazole.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Brexpiprazole_3D_ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 240
- Drug.tradename
- Rexulti, Rxulti, others
- Drug.DailyMedID
- Brexpiprazole
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.class
- Atypical antipsychotic
- Drug.ATC_prefix
~9 min read
Article
22 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- History
- Clinical trials
- Major depressive disorder
- Phase II
- Phase III
- Adult attention deficit hyperactivity disorder
- Schizophrenia
- Phase I
- Phase II
- Phase III
- Agitation associated with dementia due to Alzheimer's disease
- Society and culture
- Legal status
- Economics
- Patents
- Research
- References
- External links
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.
The most common side effects include akathisia (a constant urge to move) and weight gain. The most common side effects among people with agitation associated with dementia due to Alzheimer's disease include headache, dizziness, urinary tract infection, nasopharyngitis, and sleep disturbances (both somnolence and insomnia).